Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Twelve years of assessing the quality of preimplantation genetic testing for monogenic disorders

ZC. Deans, A. Biricik, M. De Rycke, GL. Harton, M. Hornak, F. Khawaja, C. Moutou, J. Traeger-Synodinos, P. Renwick

. 2023 ; 43 (4) : 506-515. [pub] 20221118

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc23010595

Grantová podpora
CPA UK (Ltd)

OBJECTIVE: Genomics Quality Assessment has provided external quality assessments (EQAs) for preimplantation genetic testing (PGT) for 12 years for eight monogenic diseases to identify sub-optimal PGT strategies, testing and reporting of results, which can be shared with the genomics community to aid optimised standards of PGT services for couples. METHOD: The EQAs were provided in two stages to mimic end-to-end protocols. Stage 1 involved DNA feasibility testing of a couple undergoing PGT and affected proband. Participants were required to report genotyping results and outline their embryo testing strategy. Lymphoblasts were distributed for mock embryo testing for stage 2. Submitted clinical reports and haplotyping results were assessed against peer-ratified criteria. Performance was monitored to identify poor performance. RESULTS: The most common testing methodology was short tandem repeat linkage analysis (59%); however, the adoption of single nucleotide polymorphism-based platforms was observed and a move from blastomere to trophectoderm testing. There was a variation in testing strategies, assigning marker informativity and understanding test limitations, some clinically unsafe. Critical errors were reported for genotyping and interpretation. CONCLUSION: EQA provides an overview of the standard of preimplantation genetic testing-M clinical testing and identifies areas of improvement for accurate detection of high-risk embryos.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23010595
003      
CZ-PrNML
005      
20230801132525.0
007      
ta
008      
230718s2023 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1002/pd.6263 $2 doi
035    __
$a (PubMed)36371615
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Deans, Zandra C $u GenQA, Department of Laboratory Medicine, Royal Infirmary of Edinburgh, NHS Lothian, Edinburgh, UK $1 https://orcid.org/0000000193616012
245    10
$a Twelve years of assessing the quality of preimplantation genetic testing for monogenic disorders / $c ZC. Deans, A. Biricik, M. De Rycke, GL. Harton, M. Hornak, F. Khawaja, C. Moutou, J. Traeger-Synodinos, P. Renwick
520    9_
$a OBJECTIVE: Genomics Quality Assessment has provided external quality assessments (EQAs) for preimplantation genetic testing (PGT) for 12 years for eight monogenic diseases to identify sub-optimal PGT strategies, testing and reporting of results, which can be shared with the genomics community to aid optimised standards of PGT services for couples. METHOD: The EQAs were provided in two stages to mimic end-to-end protocols. Stage 1 involved DNA feasibility testing of a couple undergoing PGT and affected proband. Participants were required to report genotyping results and outline their embryo testing strategy. Lymphoblasts were distributed for mock embryo testing for stage 2. Submitted clinical reports and haplotyping results were assessed against peer-ratified criteria. Performance was monitored to identify poor performance. RESULTS: The most common testing methodology was short tandem repeat linkage analysis (59%); however, the adoption of single nucleotide polymorphism-based platforms was observed and a move from blastomere to trophectoderm testing. There was a variation in testing strategies, assigning marker informativity and understanding test limitations, some clinically unsafe. Critical errors were reported for genotyping and interpretation. CONCLUSION: EQA provides an overview of the standard of preimplantation genetic testing-M clinical testing and identifies areas of improvement for accurate detection of high-risk embryos.
650    _2
$a těhotenství $7 D011247
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    12
$a preimplantační diagnóza $x metody $7 D019836
650    _2
$a genetické testování $x metody $7 D005820
650    _2
$a blastocysta $7 D001755
650    _2
$a aneuploidie $7 D000782
655    _2
$a časopisecké články $7 D016428
700    1_
$a Biricik, Anil $u Eurofins Genoma Laboratories, Rome, Italy
700    1_
$a De Rycke, Martine $u Centre for Medical Genetics, Universitair Ziekenhuis Brussel, Brussels, Belgium
700    1_
$a Harton, Gary L $u BioSkryb Genomics, Durham, North Carolina, USA
700    1_
$a Hornak, Miroslav $u Laboratory for Medical and Reproductive Genetics, REPROMEDA Biology Park, Brno, Czechia, USA
700    1_
$a Khawaja, Farrah $u GenQA, Department of Laboratory Medicine, Royal Infirmary of Edinburgh, NHS Lothian, Edinburgh, UK
700    1_
$a Moutou, Céline $u Laboratoire de Diagnostic préimplantatoire, Hôpitaux Universitaires de Strasbourg, Université de Strasbourg, Strasbourg, France
700    1_
$a Traeger-Synodinos, Jan $u Laboratory of Medical Genetics, St. Sophia's Children's Hospital, National and Kapodistrian University of Athens, Athens, Greece
700    1_
$a Renwick, Pamela $u Centre for Preimplantation Genetic Diagnosis, Guys Hospital, Guys and St Thomas' NHS Foundation, London, UK
773    0_
$w MED00003882 $t Prenatal diagnosis $x 1097-0223 $g Roč. 43, č. 4 (2023), s. 506-515
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36371615 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230718 $b ABA008
991    __
$a 20230801132522 $b ABA008
999    __
$a ok $b bmc $g 1963184 $s 1196860
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 43 $c 4 $d 506-515 $e 20221118 $i 1097-0223 $m Prenatal diagnosis $n Prenat Diagn $x MED00003882
GRA    __
$p CPA UK (Ltd)
LZP    __
$a Pubmed-20230718

Najít záznam

Citační ukazatele

Možnosti archivace